{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:06:47Z","timestamp":1789531607521,"version":"build-2803163510"},"reference-count":19,"publisher":"Akademiai Kiado Zrt.","issue":"37","license":[{"start":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T00:00:00Z","timestamp":1789257600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2026,9,13]]},"abstract":"<jats:p>\n                    <jats:italic>Bevezet\u00e9s:<\/jats:italic>\n                    Az onkoteambizotts\u00e1g az adott int\u00e9zm\u00e9ny onkol\u00f3giai\n                    ell\u00e1t\u00e1s\u00e1nak egyik meghat\u00e1roz\u00f3 eleme. Az onkoteam megbesz\u00e9l\u00e9sein bemutatott\n                    esetek nyilv\u00e1ntart\u00e1sa a munkacsoport m\u0171k\u00f6d\u00e9s\u00e9nek k\u00f6vet\u00e9s\u00e9re is alkalmas.\n                    <jats:italic>M\u00f3dszer:<\/jats:italic>\n                    A Gy\u0151r-Moson-Sopron V\u00e1rmegyei Petz Alad\u00e1r K\u00f3rh\u00e1z\n                    uroonkoteam-bizotts\u00e1g\u00e1ban bemutatott betegeket 2017 \u00e9s 2024 k\u00f6z\u00f6tt prospekt\u00edv\n                    k\u00f6vet\u00e9sre r\u00f6gz\u00edtett\u00fck. A jelen k\u00f6zlem\u00e9nyben az \u00e9ves betegforgalmi adatok\n                    alakul\u00e1s\u00e1t mutatjuk be.\n                    <jats:italic>Eredm\u00e9nyek:<\/jats:italic>\n                    A szervre lokaliz\u00e1lt\n                    betegs\u00e9g miatt kezelt prosztata-, h\u00f3lyag- \u00e9s vesedaganatos betegek sz\u00e1ma\n                    jelent\u0151sen n\u0151tt. Az \u00e1tt\u00e9tes prosztata- \u00e9s h\u00f3lyagdaganatos betegek sz\u00e1ma ezzel\n                    p\u00e1rhuzamosan fokozatosan cs\u00f6kkent, az \u00e1tt\u00e9tes vesedaganatos betegek sz\u00e1ma pedig\n                    nem v\u00e1ltozott. Az \u00e1tt\u00e9tes betegek ar\u00e1nya a korai st\u00e1diumban ell\u00e1tott betegekhez\n                    k\u00e9pest prosztatadaganatra vonatkoz\u00f3an 1\u00a0:\u00a01.2-r\u0151l 1\u00a0:\u00a04.6-ra, h\u00f3lyagdaganatra\n                    vonatkoz\u00f3an 1\u00a0:\u00a03.0-r\u00f3l 1\u00a0:\u00a05.4-re, vesedaganatra vonatkoz\u00f3an 1\u00a0:\u00a05.4-r\u0151l\n                    1\u00a0:\u00a06.7-re cs\u00f6kkent. Az id\u0151szak v\u00e9g\u00e9n voltak olyan \u00e9vek, amikor kevesebb mint \u00f6t\n                    \u00e1tt\u00e9tes h\u00f3lyagdaganatos beteget vesztett\u00fcnk el \u00e9vente k\u00f3rh\u00e1zunkban.\n                    <jats:italic>K\u00f6vetkeztet\u00e9s:<\/jats:italic>\n                    A betegsz\u00e1m n\u00f6veked\u00e9se \u00e9s az \u00e1tt\u00e9tes betegek\n                    ar\u00e1ny\u00e1nak cs\u00f6kken\u00e9se is a betegell\u00e1t\u00e1s min\u0151s\u00e9g\u00e9nek kedvez\u0151 mutat\u00f3i. Orv Hetil.\n                    2026; 167(37): 1477\u20131482.\n                  <\/jats:p>","DOI":"10.1556\/650.2026.33636","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T03:24:02Z","timestamp":1789529042000},"page":"1477-1482","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":0,"title":["Az uroonkol\u00f3giai ell\u00e1t\u00e1s eredm\u00e9nyess\u00e9g\u00e9nek javul\u00e1sa egy megyei centrum 10 \u00e9ves betegforgalmi adatainak t\u00fckr\u00e9ben"],"prefix":"10.1556","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8324-1971","authenticated-orcid":true,"given":"Tam\u00e1s","family":"Kullmann","sequence":"first","affiliation":[{"name":"Gy\u0151r-Moson-Sopron V\u00e1rmegyei Petz Alad\u00e1r Egyetemi Oktat\u00f3 K\u00f3rh\u00e1z, Onkoradiol\u00f3giai Oszt\u00e1ly Gy\u0151r Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"Ker\u00e9nyi","sequence":"additional","affiliation":[{"name":"Gy\u0151r-Moson-Sopron V\u00e1rmegyei Petz Alad\u00e1r Egyetemi Oktat\u00f3 K\u00f3rh\u00e1z, Urol\u00f3giai Oszt\u00e1ly Gy\u0151r Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Szepesv\u00e1ry","sequence":"additional","affiliation":[{"name":"Gy\u0151r-Moson-Sopron V\u00e1rmegyei Petz Alad\u00e1r Egyetemi Oktat\u00f3 K\u00f3rh\u00e1z, Urol\u00f3giai Oszt\u00e1ly Gy\u0151r Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"R1","unstructured":"Ministry of Health, Social and Family Affairs. Decree 60\/2003 (X.\n                    20.) on the minimum professional requirements for the provision of health\n                    services - Collection of legislation in force. [60\/2003. (X. 20.) ESzCsM\n                    rendelet az eg\u00e9szs\u00e9g\u00fcgyi szolg\u00e1ltat\u00e1sok ny\u00fajt\u00e1s\u00e1hoz sz\u00fcks\u00e9ges szakmai\n                    minimumfelt\u00e9telekr\u0151l - Hat\u00e1lyos jogszab\u00e1lyok gy\u0171jtem\u00e9nye.] Available from:\n                        https:\/\/net.jogtar.hu\/jogszabaly?docid=a0300060.esc [accessed: 20\n                    April, 2026]. [Hungarian]"},{"key":"R2","unstructured":"Ministry of Human Capacities. Decree 1\/2012 (V. 31.) amending ESzCsM\n                    Decree 60\/2003 (X. 20.) on the minimum professional requirements for the\n                    provision of healthcare services and E\u00fcM Decree 2\/2004 (XI. 17.) on the register\n                    of healthcare providers and their operating licenses, as well as on the\n                    professional healthcare registry - National Law Library. [1\/2012. (V. 31.) EMMI\n                    rendelet az eg\u00e9szs\u00e9g\u00fcgyi szolg\u00e1ltat\u00e1sok ny\u00fajt\u00e1s\u00e1hoz sz\u00fcks\u00e9ges szakmai\n                    minimumfelt\u00e9telekr\u0151l sz\u00f3l\u00f3 60\/2003. (X. 20.) ESZCSM rendelet \u00e9s az eg\u00e9szs\u00e9g\u00fcgyi\n                    szolg\u00e1ltat\u00f3k \u00e9s m\u0171k\u00f6d\u00e9si enged\u00e9ly\u00fck nyilv\u00e1ntart\u00e1s\u00e1r\u00f3l, valamint az eg\u00e9szs\u00e9g\u00fcgyi\n                    szakmai jegyz\u00e9kr\u0151l sz\u00f3l\u00f3 2\/2004. (XI. 17.) E\u00fcM rendelet m\u00f3dos\u00edt\u00e1s\u00e1r\u00f3l - Nemzeti\n                    Jogszab\u00e1lyt\u00e1r.] Available from:\n                        https:\/\/njt.jog.gov.hu\/jogszabaly\/2012-1-20-5H [accessed: 20\n                    April, 2026]. [Hungarian]"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Kullmann T, Kocsis K, Szepesv\u00e1ry Z, et al. Five-year follow-up of a\n                    single centre uro-oncology tumour board decisions. Discov Health Systems 2025;\n                    4: 48. https:\/\/doi.org\/10.1007\/s44250-025-00224-8","DOI":"10.1007\/s44250-025-00224-8"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Szigeti A, Kocsis K, Ambrus A, et al. A single centre pilot\n                    experience with 18F-JK-PSMA-7 PET-CT in the staging of prostate\n                    cancer. J Men\u2019s Health 2022; 18: 1-4.\n                        https:\/\/doi.org\/10.31083\/jomh.2021.133","DOI":"10.31083\/jomh.2021.133"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Briganti A, Chun FK, Salonia A, et al. Validation of a nomogram\n                    predicting the probability of lymph node invasion among patients undergoing\n                    radical prostatectomy and an extended pelvic lymphadenectomy. Eur Urol. 2006;\n                    49: 1019-1026.\n                    https:\/\/doi.org\/10.1016\/j.eururo.2006.01.043","DOI":"10.1016\/j.eururo.2006.01.043"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Sargos P, Chabaud S, Latorzeff I, et al. Adjuvant radiotherapy\n                    versus early salvage radiotherapy plus short-term androgen deprivation therapy\n                    in men with localised prostate cancer after radical prostatectomy (GETUG-AFU\n                    17): a randomised, phase 3 trial. Lancet Oncol. 2020; 21: 1341-1352.\n                        https:\/\/doi.org\/10.1016\/S1470-2045(20)30454-X","DOI":"10.1016\/S1470-2045(20)30454-X"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"N\u00e1dasdy-Horv\u00e1th D, Piroska M, Czibor S, et al. 18F-PSMA\n                    PET\/CT imaging following biochemical recurrence of prostate cancer. [18F-PSMA\n                    PET\/CT vizsg\u00e1lat prosztatar\u00e1k biok\u00e9miai ki\u00fajul\u00e1s\u00e1t k\u00f6vet\u0151en.] Orv Hetil. 2025;\n                    166: 2018-2023. [Hungarian]\n                    https:\/\/doi.org\/10.1556\/650.2025.33441","DOI":"10.1556\/650.2025.33441"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in\n                    metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015; 373: 737-746.\n                        https:\/\/doi.org\/10.1056\/NEJMoa1503747","DOI":"10.1056\/NEJMoa1503747"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard\n                    first-line therapy in metastatic prostate cancer. N Engl J Med. 2019; 381:\n                    121-131. https:\/\/doi.org\/10.1056\/NEJMoa1903835","DOI":"10.1056\/NEJMoa1903835"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Fizazi K, Tran NP, Fein L, et al. Abiraterone plus prednisone in\n                    metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017; 377:\n                    352-360. https:\/\/doi.org\/10.1056\/NEJMoa1704174","DOI":"10.1056\/NEJMoa1704174"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"De Bono JS, Hardy-Bessard AC, Kim CS, et al. Phase III\n                    non-inferiority study of cabazitaxel (C) 20 mg\/m2 (C20) versus 25\n                        mg\/m2 (C25) in patients (pts) with metastatic\n                    castration-resistant prostate cancer (mCRPC) previously treated with docetaxel\n                    (D). J Clin Oncol. 2016; 34(15): 5008.\n                        https:\/\/doi.org\/10.1200\/JCO.2016.34.15_suppl.5008","DOI":"10.1200\/JCO.2016.34.15_suppl.5008"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Kullmann T, Kocsis K, Ambrus A et al. Optimisa\/tion of second line\n                    antihormonal treatment for castration resistant metastatic prostate cancer. J\n                    Men\u2019s Health 2022; 18: 93.\n                    https:\/\/doi.org\/10.31083\/j.jomh1804093","DOI":"10.31083\/j.jomh1804093"},{"key":"R13","unstructured":"Kullmann T, Szepesv\u00e1ry Zs, Kocsis K. Treatment of prostate cancer.\n                    [A prosztatar\u00e1k kezel\u00e9se.] Klin Onkol. 2017; 4: 283-288.\n                    [Hungarian]"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Fizazi K, Attard G, Azad AA. Advanced and metastatic prostate\n                    cancer: ESMO clinical practice guidelines for diagnosis, treatment and\n                    follow-up. Ann Oncol. 2026; 37: 590-607.\n                        https:\/\/doi.org\/10.1016\/j.annonc.2026.01.015","DOI":"10.1016\/j.annonc.2026.01.015"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Kr\u00e1nitz N, Szepesv\u00e1ry Zs, Kocsis K, et al. Neuroendocrine cancer of\n                    the prostate. Pathol Oncol Res. 2020; 26: 1447-1450.\n                        https:\/\/doi.org\/10.1007\/s12253-019-00712-2","DOI":"10.1007\/s12253-019-00712-2"},{"key":"R16","doi-asserted-by":"crossref","unstructured":"Vale C. Neoadjuvant chemotherapy in invasive bladder cancer: a\n                    systematic review and meta-analysis. Lancet 2003; 361(9373): 1927-1934.\n                        https:\/\/doi.org\/10.1016\/S0140-6736(03)13580-5","DOI":"10.1016\/S0140-6736(03)13580-5"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Powles T, Catto JW, Galsky MD, et al. Perioperative durvalumab with\n                    neoadjuvant chemotherapy in operable bladder cancer. N Engl J Med. 2024; 391:\n                    1773-1786. https:\/\/doi.org\/10.1056\/NEJMoa2408154","DOI":"10.1056\/NEJMoa2408154"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Abbas W, Goel V, Verma A, et al. Harnessing the immunomodulatory\n                    effects of radiation in urinary bladder cancer. Cureus 2019; 11: e4108.\n                        https:\/\/doi.org\/10.7759\/cureus.4108","DOI":"10.7759\/cureus.4108"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Loehrer PJ Sr., Gonin R, Nichols CR, et al. Vinblastine plus\n                    ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell\n                    tumor. J Clin Oncol.1998; 16: 2500-2504.\n                        https:\/\/doi.org\/10.1200\/JCO.1998.16.7.2500","DOI":"10.1200\/JCO.1998.16.7.2500"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/167\/37\/article-p1477.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/167\/37\/article-p1477.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/167\/37\/article-p1477.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T03:24:17Z","timestamp":1789529057000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/167\/37\/article-p1477.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,13]]},"references-count":19,"journal-issue":{"issue":"37"},"URL":"https:\/\/doi.org\/10.1556\/650.2026.33636","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,13]]}}}